ORIC

For ORIC Pharmaceuticals, the modeled fair value price target has shifted from US$20.67 to US$21.93, a small change that still matters if you are tracking how analysts frame the story.

Key TakeawaysORIC Pharmaceuticals shares fell 22% today after Johnson & Johnson presented early data for JNJ-6143, a rival prostate cancer drug.

Oric Pharmaceuticals (NASDAQ:ORIC) reported updated Phase 1b data for enozertinib in previously untreated patients with advanced non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations, highlighting systemic and intracranial responses in a cohort…

ORIC Pharmaceuticals reported that it held a conference call and webcast on October 23, 2026 to review Phase 1b data for enozertinib in first line non small cell lung cancer patients with EGFR atypical mutations following presentation of the data at the ESMO…

In October 2026, ORIC Pharmaceuticals announced that Cancer Research UK’s Centre for Drug Development will fully fund, sponsor, design, and conduct CTA-enabling studies and early clinical development of ORIC-259, a potential first-in-class CIP2A-targeted…

ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target

On August 3, ORIC Pharmaceuticals (NASDAQ:ORIC) reported second-quarter results that showed a clinical-stage biotech converting years of early work into two separate late-stage bets at once.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc.